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Introduction: High-dose chemotherapy (HDC) followed by
auto-HCT can be performed in the outpt setting in selected
pts and may be as safe and more cost effective than in the
inpt setting. We evaluated the role of HCT-CI on the charac-
teristics and outcomes of pts with MMwho underwent auto-
HCT in both inpt and outpt settings between January 2008
and December 2012 at our institution.
Methods: We identiﬁed a total of 1046 pts, with 669 trans-
planted as inpts and 377 as outpts. Primary endpoints were
incidence of unscheduled admissions, treatment-related
mortality (TRM), grade 2-4 adverse events (AEs), deﬁned by
the National Cancer Institute’s Common Terminology
Criteria, version 4, and average cost of auto-HCT in both inpt
and outpt groups. Secondary endpoints were overall
response (OR) rates, progression-free survival (PFS), and
overall survival (OS).
Results: Median age at auto-HCT was 62 (range, 31-82) in
inpts and 58 (range, 34-78) years in outpts, (p<0.001).
HCT-CI score was 3 in 55% inpts vs 45% outpts (p¼.003).
There was no signiﬁcant difference in baseline cytogenetic
abnormalities, serum LDH or ISS stage II/III between the 2
groups. Forty-four (6.6%) inpts and 7 (2%) outpts had serum
creatinine of 2 mg/dL (p¼<0.001). Twenty-nine percent
of inpts vs. 21% of outpts had relapsed disease at auto-HCT
(p¼0.02). Median follow up in inpts vs. outpts was 14 and
15 months, respectively. One-hundred day TRM was 1.5% inFigure 1. 2-Year Progression Free Survivalinpts vs. 0.3% in outpts (p¼0.09). Grade 2-4 AEs were seen
in 552 (83%) inpts vs. 277 (73%) outpts (p¼0.001); grade 3-
4 in 359 (54%) inpts vs. 163 (43%) outpts (p¼0.001); and
grade 4 in 19 (3%) inpts vs. 6 (2%) outpts (p¼0.2). OR rates
were signiﬁcantly better in outpts, with 364 (96.5%) outpts
with PR vs. 599 (89%) inpts (p<0.001). Subsequent un-
scheduled hospitalizations were required in 208 (55%)
outpts, with neutropenic or non-neutropenic fever being
the most common reason (157 pts: 42%). On multivariate
analyses, an HCT-CI score of >2 and relapsed disease at
auto-HCT were associated with increased incidence of
unscheduled hospitalization. Outpts had signiﬁcantly
longer 2-year PFS (60% vs. 50%, p¼0.005, HR 0.7, 95% CI 0.6-
0.9) (Figure 1) and OS (83% vs. 77%, p¼0.01, HR 0.6, 95% CI
04-0.9) (Figure 2). The average cost of auto-HCT from the
date of original consult to day +30 was $416,154 for inpts
and $292,572 for outpts.
Discussion: In this study, pts selected for auto-HCT in the
outpt setting were younger, had a lower HCT-CI score and a
signiﬁcantly better renal function at diagnosis. A lower HCT-
CI score and auto-HCT in ﬁrst remission predict a lower risk
of unscheduled hospitalization, with a cost savings of
approximately $125,000 for those who received auto-HCT in
the outpt setting. Appropriately selected pts with MM can
safely undergo auto-HCT in the outpt setting without any
signiﬁcant increase in toxicity or TRM, and a signiﬁcant
decrease in transplant costs.116
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Background: Children with high-risk SCD have a high risk
of chronic morbidity and early mortality and can only be
cured following a successful allogeneic stem cell trans-
plant (AlloSCT) (Talano/Cairo et al, EJH, 2014). We previ-
ously demonstrated 100% EFS/overall survival in 18
children with SCD following reduced toxicity conditioning
and HLA matched sibling or cord blood (CB) AlloSCT
(Bhatia/Cairo et al, BMT, 2014). All sibling donors with SCD
trait were mobilized with G-CSF without serious adverse
events. Unfortunately, high-risk SCD patients have only a
16% chance of having an unaffected HLA matched sibling
donor (Freed/Cairo et al, BMT, 2012). Previous studies by
our group and others utilizing unrelated CB as alternative
donors had unsatisfactory results (Radhakrishnan/Cairo et
al, BBMT, 2013; Kamani/Shenoy et al, BBMT, 2012). Few 8/8
HLA matched unrelated donors have been identiﬁed in the
unrelated donor registries. Haploidentical maternal do-
nors with SCD trait open up a major opportunity to
identify a new donor source in children with high-risk
SCD. Past studies reported serious toxicity of G-CSF
mobilization in patients with homozygous SCD (Adler/
Prchal et al, Blood, 2001). There is a paucity of information
of safety and efﬁcacy of G-CSF PBSC mobilization from
haploidentical adult maternal donors with SCD trait.Objective: To determine the safety and efﬁcacy of G-CSF
PBSC mobilization in haploidentical parental donors with
sickle cell trait.
Methods: G-CSF (15mcg/kg/d divided bid x 4 days) was
administered to seven haploidentical maternal donors with
sickle cell trait; PBSC collection was on day 5. Donors un-
derwent 1 rounds of PBSC leukapheresis using the Spectra
Optia (n¼6) or Spectra (n¼1) Apheresis System. A minimum
of 10 x 106 CD34/kg and 2 x 105 CD3/kg were obtained and
cryopreserved prior to beginning of recipient myeloablative
conditioning prior to Day -59. PBSCs were selected by the
CliniMACS System (Miltenyi Biotec) and 2 x 105 CD3/kg was
added back prior to infusion (Fig. 1A).
Results: Seven haploidentical adult maternal donors were
mobilized with G-CSF x4 days (median age 46 [34-55] yrs)
with a meanSEM CD34/kg (recipient weight) was of 20.9 
3.32 x 106/kg and a ﬁnal meanSEM selection of 14.51.54 x
106/kg (Fig. 1B). There was Grade 1 generalized bone pain
(NIH CTCAE, V4.0,) but no episodes of SCD-related
venoocclusive crisis, stroke, acute chest syndrome or other
adverse events (Fig. 1B).
Conclusion: These preliminary data suggest that G-CSF
mobilization of PBSC in haploidentical adult maternal
donors with SCD trait was safe, well-tolerated and
resulted in desired efﬁcacy. A larger cohort and with
longer follow-up will be required to conﬁrm the pre-
liminary ﬁndings. (This study was supported by grants
Abstracts / Biol Blood Marrow Transplant 21 (2015) S114eS126S116from the FDA [5R01FD004090] and Otsuka and
CliniMACS supplies from Miltenyi Biotec) (IND#14359
and NCT01461837; http://www.sicklecelltransplantconsor
tium.org).
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Hematopoietic Cell Transplant (HCT) patients are often
medically and psychosocially complex requiring extended
clinician visits that are frequently carried out by Advanced
Practice Practitioners (APP’s). Recent HCT medical advances
have reduced treatment mortality. Knowledge of HCT sur-
vivor needs are necessary for both oncology and primary care
APP’s to effectively collaborate to promote optimal care,
especially given the projected physician shortages as well as
APP training which focuses on health promotion and main-
tenance strategies.
Evidence-based guidelines for standards of care in HCT
survivors were revised in 2012. These guidelines augment
the foundation for extending longevity. Our research sought
to explore unmet adult survivorship needs in patients one
year or greater post-HCT.We sought information to elucidate
treatment centered survivorship characteristics associated
with adherence to the evidence-based HCT guidelines and
general health screening recommendations. Lastly, we
attempted to identify and compare features of unmet adult
survivorship needs between allogeneic and autologous HCT
survivors.
A cross-sectional pilot study utilizing the University of
Waterloo’s Unmet Needs: A survey for people touched by
cancer (SUN) was employed to examine the unmet needs of
HCT survivors. SUN has a reported Cronbach’s alpha indi-
cating strong psychometric properties. Statistical measures
included descriptive statistics and analysis of variance with
statistical signiﬁcance set at p¼0.05.
The overall survey response rate was 52%, with greater
than 50% of male gender, 67% married, and >90% Caucasian.
Additional demographic details will be presented in table
format. Within the unmet information needs domain,
greater than 55% of respondents noted a need for assistance
in dealing with anxiety and worry between follow-up visits.
40% of respondents noted fatiguewithmost household tasks,
even up to 5 years post-transplant. Relationship domain
analysis revealed that greater than 40% of participants had
difﬁculty in dealing with reactions to newly established
priorities and goals based on their survivorship status. Sur-
vivors noted hardship dealing with the strains that cancerFigure 1. View of the BMT Database main form. Fields outlined in red are automatic
button automatically compiles and attaches the PDF request document to an outgoinput on their relationship. Greater than 66% of respondents
over age 50 reported never having had a colonoscopy. Full
dermatologic evaluation was lacking in 70% of post BMT
patients. Similar issues existed regardless of type of trans-
plant.TRANSPLANT DATA MANAGEMENT118
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Introduction: Requesting follow-up information on BMT
patients from external providers is an ongoing task for BMT
staff. By automating the faxing request process, the UIHC
BMT Data Team saves time and resources by eliminating the
need to edit and track paper documents and by reducing
printing supply costs.
Methods: Data Manager-speciﬁc reports with contact in-
formation and signature images were created in our BMT
Access Database from previously used document tem-
plates. Key ﬁelds from the main database table that we
wanted to automatically generate from the data already
entered in the patient’s record were pulled into the report
and validated. Because each recipient’s forms require
reporting at different times based on date of transplant,
the request time frame was created by inserting the “Date
of Last Contact” ﬁeld and adding a new calculated ﬁeld
which auto-populates the current date within the report
once the button is clicked. A separate button exists to view
the reports before faxing for information to ensure
completeness. Our hospital supports inbound and
outbound faxing through Microsoft Outlook, so I custom-
ized a Visual Basic (VBA) event procedure within Access
which compiles our follow-up request report into PDF
format, based upon the record displayed, and automati-
cally attaches it to an outlook email message with the
subject “Request for follow-up information.” After
entering the referring provider fax number the request can
be sent.
Conclusion: Having the ability to instantly fax referring
providers for information has saved resources and decreased
the time spent by the BMT Data Team on this activity by
more than 75%. Current efforts are underway to customize
and automate all patient and provider contact letters and
requests for more positions within the BMT program. As a
result, we fully expect to maximize staff time and save pro-
gram resources.ally populated into the request for information report. Clicking the “Fax MD”
g message from the Data Manager’s Outlook.
